PHAP pushes lifelong immunization access
Daily TribuneThe Pharmaceutical and Healthcare Association of the Philippines (PHAP) is on a mission to ensure that every Filipino, from infants to seniors, has access to life-saving vaccines.
As World Immunization Week wraps up, PHAP is doubling down on its commitment through its “IBA ang Bakunado” campaign.
This initiative emphasizes the importance of timely and lifelong immunization, aiming to protect individuals against over 30 preventable diseases, including measles, polio, flu, pneumonia, hepatitis, cervical cancer, and emerging respiratory illnesses.
PHAP executive director Teodoro Padilla highlights the cost-effectiveness of vaccination programs, noting that for every P100 invested, the healthcare system can save up to P5,400. “That’s a real, measurable impact — for families, our healthcare system and the nation as a whole,” Padilla says.
PHAP president Dr. Diana Edralin stresses the need for continuous innovation and investment in vaccines to address both current and future health threats. “Continuous investment in life-course immunization, modernizing healthcare systems and adopting new vaccines are all critical to future-proofing our public health defenses,” Edralin adds.
The campaign also aligns with the Department of Health’s 8-point agenda and its 2025 World Immunization Week theme, “Magpabakuna: Bakuna sa lahat, kayang-kaya!”
PHAP’s advocacy builds on lessons learned from the Covid-19 pandemic, underscoring the urgent need for collective action to close immunization gaps and strengthen universal protection.
PHAP member companies — including Abbott, GSK, MSD, Pfizer, Sanofi, Takeda and Zuellig Pharma — are collaborating to ensure timely access to vaccines by advancing scientific research, strengthening global and local partnerships, and enhancing supply chain networks.
The association also advocates for the introduction of new and innovative vaccines already approved and in use internationally, targeting diseases such as dengue, shingles, invasive meningococcal disease and respiratory syncytial virus. Expanding coverage for these vaccine-preventable diseases represents a critical step forward in enhancing public health.